Wegovy (semaglutide 2.4mg) is the FDA-approved weight loss version of Ozempic, specifically formulated for chronic weight management. Clinical trials show users losing an average of 15-20% of their body weight over 68 weeks. But rapid fat loss comes with a tradeoff many don't anticipate: facial volume loss, sagging skin, and the dreaded "Wegovy face." Our AI transformation visualizer shows you BOTH outcomes—what rapid, unmanaged weight loss looks like versus a healthy transformation with muscle retention—so you can plan your approach before losing a single pound.
What rapid weight loss looks like: gaunt cheeks, hollow temples, aged appearance.
What healthy transformation looks like: defined jawline, volume retention, radiant appearance.
Upload a photo to generate your personalized preview.
Full body shots or face close-ups supported
100% Private: We never store your original photo. Generated images are automatically permanently deleted after 1 hour.
Three simple steps to your new look.
Use a clear, full-body photo with good lighting for the best results.
Select "Lose Weight", "Muscle Gain", or "Shred" to guide our engine.
Our system processes your image and delivers a high-fidelity preview in seconds.
The same weight loss can look completely different depending on how you lose it. See all three stages of your transformation journey.
Your starting point before any weight loss
Your starting point before any weight loss
Rapid weight loss without proper nutrition - gaunt, hollow appearance
Healthy transformation with muscle retention - defined, glowing
Wegovy is the higher-dose, weight-loss-specific formulation of semaglutide (2.4mg vs Ozempic's 0.5-1mg). While both medications use the same active ingredient, Wegovy is specifically FDA-approved for chronic weight management in adults with obesity or overweight conditions. The higher dosage leads to more pronounced appetite suppression and weight loss, which is why it's crucial to approach your journey with proper nutrition and strength training.
Wegovy's higher 2.4mg dosage makes it more potent than Ozempic, with clinical trials showing 15-20% body weight loss over 68 weeks. This effectiveness is a double-edged sword: the stronger appetite suppression means you need to be even more disciplined about protein intake. Many Wegovy users report feeling so full that eating their protein target feels like a chore—but skipping it leads directly to muscle loss and facial volume depletion. Because Wegovy is specifically formulated for weight loss (not diabetes management), users often lose weight faster than Ozempic users. This makes the difference between "gaunt" and "glow" even more pronounced. Our visualizer shows you what 15-20% body weight loss looks like both ways, so you understand why resistance training and adequate protein aren't optional—they're the difference between looking sick and looking vibrant.
Three simple steps to see your transformation paths
Use any clear photo of yourself. Full body works best, but face photos work too. The AI analyzes your facial structure and fat distribution.
Choose "Wegovy Transformation (Both Paths)" to see side-by-side comparisons of rapid loss versus healthy transformation. The AI generates both versions.
See both versions side-by-side. Use them to inform your nutrition strategy, training plan, and weight loss pacing decisions. Knowledge is power.
Explore our full suite of weight loss medication visualizers
See both transformation paths before you start
See realistic Ozempic transformation results
Visualize Mounjaro transformation results
See semaglutide facial transformation effects
Preview tirzepatide weight loss results
See Zepbound transformation results
Both contain semaglutide, but Wegovy is the higher-dose (2.4mg) version specifically FDA-approved for weight loss, while Ozempic (0.5-1mg) is approved for type 2 diabetes with weight loss as a side effect. Wegovy typically produces more significant weight loss due to the higher dosage, which makes proper nutrition and muscle preservation even more critical to avoid facial volume loss.
Clinical trials showed participants losing an average of 15-20% of their body weight over 68 weeks (about 16 months). Individual results vary based on starting weight, adherence to the medication, diet quality, and exercise habits. Our visualizer helps you see what that weight loss might look like with different approaches to nutrition and training.
No, they're the same phenomenon—both refer to the gaunt, aged appearance from rapid weight loss on GLP-1 medications. Since Wegovy is a higher dose of the same medication (semaglutide), the risk of facial volume loss is similar or potentially higher due to more aggressive weight loss. The solution is the same: gradual weight loss with adequate protein intake and resistance training.
